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Schizophrenia is a severe and persistent mental illness and treatment is woefully
inadequate for the majority of afflicted individuals. Nearly all available antipsychotic
agents are dopamine D2, D3, and/or D4 receptor antagonists.1 More recently, partial
agonistic action at D2 and D3 receptors has suggested that this may be a promising approach.2 Three partial agonist compounds have now been approved for acute
psychosis associated with schizophrenia by the US Food and Drug Administration
(FDA): aripiprazole, brexpiprazole, and cariprazine. The newest of these, cariprazine,
has unique properties that may affect its clinical profile.
Similarly, bipolar illness is a severe, recurring illness. While psychosis is a common
symptom in manic and depressed individuals with bipolar I disorder, antipsychotic
agents have demonstrated efficacy independent of the presence of psychosis.3 Furthermore, antipsychotics with antidepressant potential have helped fulfill an unmet need
for bipolar patients.4,5 Cariprazine has been studied in this population as well.
Cariprazine is a piperazine derivative that was developed by Geoden-Richter in
Hungary. Initially, scientists identified trans-N-[4-[2-[4-(2,3-dichlorophenyl)piperazin1-yl]ethyl]cyclohexyl]-N′,N′-dimethylurea hydrochloride or “2m” as an impurity in
biosynthetic experiments.6 However, subsequent analysis revealed that this impurity
was more promising than the original research target.6 The drug was subsequently
named cariprazine (RGH-188) and investigated clinically for both schizophrenia and
depression in unipolar and bipolar illness.
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Abstract: Schizophrenia and bipolar disorder are severe psychiatric disorders that are frequently
associated with persistent symptoms and significant dysfunction. While there are a multitude
of psychopharmacologic agents are available for treatment of these illnesses, suboptimal
response and significant adverse consequences limit their utility. Cariprazine is a new, novel
antipsychotic medication with dopamine D2 and D3 partial agonist effects. Its safety and
efficacy have been investigated in acute psychosis of schizophrenia, bipolar mania, bipolar
depression, and unipolar depression. Efficacy has been demonstrated in schizophrenia and
mania. It is unclear if cariprazine is effective in depression associated with unipolar or bipolar
illness. Adverse consequences include extrapyramidal symptoms including akathisia, and
various gastrointestinal symptoms. The US Food and Drug Administration (FDA) has recently
approved cariprazine. This review will provide clinicians with basic information regarding the
research program of cariprazine.
Keywords: cariprazine, dopamine D3 receptor, dopamine D2 receptor, bipolar disorder, mania,
bipolar depression, schizophrenia
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Pharmacodynamics and
pharmacokinetics
Cariprazine is a partial agonist at the dopamine D2 and D3,
and the serotonin 5HT1A receptors.7 It has high affinity to
these receptors (Ki =0.5, 0.085, and 3.0 nM, respectively8)
as well as serotonin 5HT2B and 5HT2A receptors.8 At doses
approaching 2–3 mg per day, cariprazine receptor occupancy
easily exceeds 85% for D2 and D3 receptors in monkeys.9
In humans with schizophrenia, 1.5 mg daily will achieve
69%–75% receptor occupancy.10 In nonpsychotic controls,
doses of 1 mg daily achieve over 65% receptor occupancy.11
Serotonin 5HT1A receptor occupancy never exceeds 30%
despite a high affinity.9 Cariprazine is safe and effective in
dose ranges 3–12 mg daily.
The half-life of cariprazine is ~2–6 days.12,13 Cmax for
cariprazine is achieved in 3–4 hours after an oral dose, but
because of a half-life of 2–6 days, achieves steady state in
over a week.12,13 Furthermore, it has two active metabolites,
desmethyl-cariprazine and didesmethyl-cariprazine,14 which
prolong time to functional steady state to over 1 month.
Metabolism occurs through CYP450 3A4 and, to a lesser
extent, CYP450 2D6.15
Partial dopamine agonist antipsychotics allow clinicians
to obtain clinical efficacy while minimizing dopamine-related
adverse events (AEs). Dopamine-mediated AEs occur
when receptor occupancy exceeds 80%16 in both animals17
and humans.18,19 This is so close to the 65% D2 occupancy
which is required to achieve the antipsychotic effect20,21 that
it is difficult to titrate the dose appropriately, and clinicians
generally use antipsychotics at 90% occupancy.22
Cariprazine, and other high-affinity partial agonists, solve
this problem. When cariprazine is administered at a dose
that occupies 95% of the D2 receptors, the partial activation
produces an apparent lower level of blockade. The level of
partial activation needs to mimic the natural tonic dopamine
signal in the brain, ~20%–25% of the maximal dopamine
signal.23 Thus, partial agonists must stimulate the D2 receptor
at a level similar to this. Cariprazine may reduce the risk of
dopamine-related AEs even further due to its partial agonistic
effect on 5HT1A, which may reduce extrapyramidal symptoms and improve mood and cognition.24–26 The reduction
of D2-mediated AEs is essentially quantified in the serum
prolactin data. In long-term safety studies in patients with
schizophrenia, mean prolactin levels drop by 18.3 ng/mL at
48 weeks versus baseline (dose range from 1.9 to 9 mg/day).
While some of this reduction may be related to some of the
patients coming off a prolactin-increasing antipsychotic, the
reduction is consistent with the activation of D2 receptors
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at/near the natural tonic level of dopamine by the partial
agonist effect of the drug.
Partial agonism may also play an important role that is
specific to the pathophysiology of schizophrenia. Recent
positron emission tomography studies suggest that patients
with early or chronic schizophrenia have an increase in
dopamine synthesis and dopamine release.27–30 However,
the synaptic density is unchanged versus controls,31 suggesting that the amount of dopamine per synapse in
patients with schizophrenia is increased. Indeed, there is
evidence that in subjects with schizophrenia and at-risk
individuals, the dopamine system is hyperresponsive.30,32
A high-affinity partial agonist will fully prevent endogenous
dopamine from interacting with postsynaptic receptors while
creating a partial dopamine signal that normalizes functional
dopamine signal.
Cariprazine is generally described as a D3-preferring
agent. The D3 receptor has the highest density of expression
in the nucleus accumbens and olfactory tubercle.27–29 Overexpression of D3 reduces motivation in mice,30 and blockade
of D3 improves cognition and reduces hyperactivity in rats.31
While antipsychotics frequently block D3,32,33 and a genetic
variant of this receptor has been associated with risk of developing tardive dyskinesia,34 cariprazine is a partial agonist,
so that some stimulation of the receptor continues even at
maximal receptor occupancy. As would be expected from
the receptor profile, cariprazine has demonstrated efficacy
in animal models that examine cognition,24,35 depression,25
and mania.36

Cariprazine in schizophrenia
Four acute studies performed in subjects with schizophrenia
have either been published directly,37 or presented in meetings
and published in review format.38,39 In an early Phase II study,
392 subjects with acute schizophrenic psychosis were randomized to receive 1.5–3 mg/day or 3–6 mg/day of cariprazine or
placebo, after a 7-day washout, and followed for 6 weeks.38,39
A large fraction (46%) discontinued the study early for a variety of reasons. A larger fraction of patients receiving placebo
(15%) stopped the study for lack of efficacy than in either
active arm (8% in the low-dose arm and 9% in the high-dose
arm).38 The score of the Positive and Negative Syndrome
Scale (PANSS) improved significantly in patients receiving
1.5–3 mg/day of cariprazine compared to placebo; the higher
dose arm did not statistically separate from placebo.38
A second Phase II study which has been published40
randomized 732 subjects with acute schizophrenic psychosis
to one of five arms: cariprazine 1.5 mg/day, 3 mg/day,
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4.5 mg/day, placebo, or risperidone 4 mg/day for 6 weeks.
All active arms improved significantly compared to placebo.
There appeared to be a dose-related change in magnitude
of PANSS change with a least squares mean difference
(LSMD) of -7.6, -8.8, and -10.4 for 1.5, 3, and 4.5 mg/day
of cariprazine, respectively; risperidone change was -15.1,
but the study was not powered to examine differences in the
active arms.40
A Phase III study randomized 617 patients to cariprazine
3 mg/day or 6 mg/day, aripiprazole 10 mg/day, or placebo.
All active arms improved significantly compared to placebo.
The cariprazine 6 mg/day arm and aripiprazole group
separated from placebo at week 1; the low-dose cariprazine
arm separated from placebo at week 3 (due to the long halflife and delay in reaching steady state).38
A second Phase III study randomized 446 people with
acute schizophrenia to three arms: cariprazine 3–6 mg/day
(n=151), cariprazine 6–9 mg/day (n=1,480), and placebo
(n=147).37 Both active arms improved significantly relative
to placebo, but again there appeared to be a numerical dose
effect with LSMD of -6.8 for the low-dose arm and -9.9 for
the high-dose arm.37
Across the three published schizophrenia studies, males
outnumbered females by a ratio of approximately 3:1.37,38,40
There were no reported differences in efficacy or AEs
between the sexes.
In summary, short-term studies performed with cari
prazine in patients with acute exacerbation of schizophrenia
revealed the drug to be effective in a wide range of doses,
and revealed that the extent of improvement is similar to
established second-generation antipsychotics. There may
be evidence of dose-responsiveness in the antipsychotic
effect. This may be a true pharmacodynamics effect, or may
be related to a pharmacokinetic effect where lower doses
require a longer time to reach levels achieved at higher
doses, and steady-state levels are not achieved in the brief
6-week period.
The side-effect profile in both the short-term and longterm studies was similar for patients with bipolar illness and
patients with schizophrenia. The safety profile of cariprazine
is discussed in the following section.

Efficacy in bipolar illness
Three randomized controlled trials have been conducted in
patients with mania.38,41 A Phase II study randomized 238
adults to either a flexible-dose cariprazine (3–12 mg/day)
or placebo.41 The majority of patients (66.1%) reached
12 mg/day, and the average dose was 8.8 mg/day. 41
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The LSMD by week 3 was -6.12 points on the Young Mania
Rating Scale (YMRS) (Figure 1). Approximately, half of
the patients (48%) achieved at least a 50% improvement, or
became euthymic (42%) compared to one-quarter of placebotreated patients (25% and 23%, respectively).37,41 As with
nearly all of the cariprazine studies, dropout rates were high,
so that 61.9% (n=73) of the placebo group and 63.6% (n=75)
of the cariprazine group completed the study.37,41
Two Phase III trials with manic patients have been
presented. The first trial randomized 312 acutely manic
adults to either a flexible-dose cariprazine or placebo.
Over half of the patients responded (59%) or achieved
remission (52%) on cariprazine compared to significantly
smaller numbers on placebo (44% and 35%, respectively).42
The LSMD in YMRS score was -4.3 for the cariprazinetreated patients.42
In the second Phase III trial, 497 manic patients with
mania were randomized to cariprazine 3–6 mg/day,
6–12 mg/day, or placebo.43 The YMRS LSMD was essentially the same for both dose ranges (-6.1 points for the lower
dose and -5.9 points for the higher dose, both P,0.001).43
Only 25% of patients in this study achieved remission.
Cariprazine was also investigated as a potential antidepressant in depressed patients with bipolar and unipolar
disorders. In a Phase II study, 233 depressed subjects with
bipolar disorder were randomized to a very-low-dose arm
(0.25–0.75 mg/day), a low-dose arm (1.5–3.0 mg/day), and
placebo. There was no statistically significant separation from
placebo.44 In a subsequent study, 584 depressed patients with
bipolar disorder were treated for 8 weeks with cariprazine
0.75 mg/day, 1.5 mg/day, 3.0 mg/day, or placebo.45 The group
receiving 1.5 mg of cariprazine improved transiently at week 6
(four-point improvement on Montgomery–Åsberg Depression Rating Scale, P=0.003).45 These findings mirror other
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Figure 1 The reduction in the Young Mania Rating Scale (YMRS) for manic subjects
being treated with cariprazine and placebo over 21 days (last observation carried
forward).
Note: Data from Kane et al.37
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observations with partial agonists. Brexpiprazole, which is
a partial agonist antipsychotic drug recently approved as an
adjunct for the treatment of unipolar depression, appeared to
have a therapeutic window – in which 2 mg/day was more
effective than both 1 mg and 3 mg daily.46,47 Thus, the observation that 1.5 mg/day of cariprazine is more effective than either
a lower dose or a higher dose is not without precedent in this
class of medications. Similarly, the phenomenon of a transient
improvement was also observed with aripiprazole in bipolar
depression48 and may be a reflection of the combination of
a therapeutic window and long drug half-life. Repeating the
study with 1 mg/day for a longer time period may clarify the
actual efficacy of cariprazine in bipolar depression.
However, these conjectures are not supported by a Phase II
study where the condition of 231 patients with treatmentresistant unipolar depression receiving 0.1–0.3 mg/day or
1.0–2.0 mg/day added to an antidepressant did not improve.49
Furthermore, the condition of 819 patients who received
a higher dose of cariprazine added to an antidepressant
for 8 weeks (2.0–4.5 mg/day + antidepressant) improved
compared to placebo + antidepressant (P=0.0114).50 Thus,
cariprazine may indeed have efficacy in the treatment of
depression (unipolar and/or bipolar), but the full nature of
that effect is not clear.

Safety and tolerability
Cariprazine has been approved for use in patients with
acute exacerbation of schizophrenia and bipolar mania
(including mixed states). The AE profile in the short-term
studies in schizophrenia and bipolar disorders is very
similar.38–41,51–54
While the efficacy of cariprazine appears to be doserelated, so that doses of 3.0–4.5 mg once daily are generally
more effective than lower doses, tolerability does not appear to
be dose-related.40 In most acute studies, more placebo-treated
subjects compared to cariprazine discontinued treatment due
to insufficient therapeutic response.40 Compared to other
FDA-approved second-generation atypical antipsychotics,
cariprazine is less likely to produce clinically significant
metabolic side effects, such as weight gain, hyperlipidemia,
hypercholesterolemia, and hyperglycemia, with any
observed changes being similar to placebo.37,40,55 There are
no significant ECG abnormalities55 and prolactin levels
usually drop.55 Common AEs are either central (in order of
decreasing frequency: insomnia, extrapyramidal symptoms,
akathisia, sedation, dizziness, and anxiety) or gastrointestinal
(nausea, constipation, and vomiting).7,40,41 In patients with
bipolar illness, measuring akathisia (utilizing the Barnes
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Akathisia Rating Scale) reveals a nonsignificant increase
in akathisia with cariprazine versus placebo (0.4 vs 0.09,
P=0.12).41 However, when parkinsonism is measured by the
Simpson Angus Scale, there is a significantly greater level of
extrapyramidal symptoms in patients receiving cariprazine
(1.17) versus placebo (0.09, P,0.01).41 In most studies,
AEs did not appear to be dose related.41,55 However, in one
unpublished acute mania study, AEs occurred at greater
frequency at higher doses (6–12 mg/day) compared to lower
doses (3–6 mg/day), and both greater than placebo.7
There were no reported abnormalities in liver function
or P450 enzyme function with cariprazine treatment. However, due to the long half-life of the drug and its equipotent
active metabolites, the FDA added a warning that cariprazine may have late-occurring AEs, occurring after weeks
of treatment.
In summation, cariprazine was considered safe and well
tolerated among adult patients diagnosed with acute schizophrenia and bipolar mania.

Conclusion
Partial agonists of the dopamine system are becoming the
preferred class of medications over pure antagonists in
treatment of both psychosis and mood disturbance. This is
because tolerance to the medication is less likely to occur
when the receptor is both blocked and stimulated at the same
time. Cariprazine is a partial agonist at D2, D3, and 5HT1A
receptors. The affinity at the D3 receptor is approximately
six times greater than at the D2 receptor. However, it is
administered at a dose that generally blocks the majority of
both of these receptors.
Studies with partial agonists, particularly with long halflives are frequently difficult to predict, and this appears to be
the case with cariprazine. In studies with patients with bipolar
mania or schizophrenic psychosis, cariprazine has shown
significant efficacy and a tolerable AE profile. However, it is
much more difficult to interpret the depression data. The data
are consistent with the interpretation of a window in which the
drug may be effective with depression, in a manner similar
to aripiprazole and brexpiprazole. The task of understanding
the effect of the drug is made more difficult by the paucity of
publications of the completed clinical trials. Nonetheless, the
recent approval of cariprazine provides a new tool for clinicians, which appears to have unique mechanistic profile.
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